Phenylacetylglutamine From the Gut Microbiota: A Future Therapeutic Target in Heart Failure?

HomeCirculation: Heart FailureVol. 16, No. 1Phenylacetylglutamine From the Gut Microbiota: A Future Therapeutic Target in Heart Failure? No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextPhenylacetylglutamine From the Gut Microbiota: A Future Therapeutic Target in Heart Failure? Ayodeji Awoyemi, Johannes R. Hov and Marius Trøseid Ayodeji AwoyemiAyodeji Awoyemi https://orcid.org/0000-0001-7908-0266 Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, Norway (A.A.). Search for more papers by this author , Johannes R. HovJohannes R. Hov https://orcid.org/0000-0002-5900-8096 Norwegian PSC Research Center and Section of Gastroenterology, Department of Transplantation Medicine (J.R.H.), Oslo University Hospital, Norway. Research Institute of Internal Medicine (J.R.H., M.T.), Oslo University Hospital, Norway. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway (J.R.H., M.T.). Search for more papers by this author and Marius TrøseidMarius Trøseid Correspondence to: Marius Trøseid, MD, PhD, Research Institute of Internal Medicine, Oslo University Hospital, 0372 Oslo, Norway. Email E-mail Address: [email protected] https://orcid.org/0000-0001-7775-3404 Research Institute of Internal Medicine (J.R.H., M.T.), Oslo University Hospital, Norway. Section for Clinical Immunology and Infectious Diseases (M.T.), Oslo University Hospital, Norway. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway (J.R.H., M.T.). Search for more papers by this author Originally published16 Dec 2022https://doi.org/10.1161/CIRCHEARTFAILURE.122.010222Circulation: Heart Failure. 2023;16This article is a commentary on the followingGut Microbiota-Generated Phenylacetylglutamine and Heart FailureFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 90.Correspondence to: Marius Trøseid, MD, PhD, Research Institute of Internal Medicine, Oslo University Hospital, 0372 Oslo, Norway. Email marius.troseid@medisin.uio.noReferences1. Troseid M, Andersen GO, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: current knowledge and future directions.EBioMedicine2020; 52:102649. doi: 10.1016/j.ebiom.2020.102649CrossrefMedlineGoogle Scholar2. Nemet I, Saha PP, Gupta N, Zhu W, Romano KA, Skye SM, Cajka T, Mohan ML, Li L, Wu Y, et al. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors.Cell2020; 180:862–877.e22. doi: 10.1016/j.cell.2020.02.016CrossrefMedlineGoogle Scholar3. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.N Engl J Med. 2013; 368:1575–1584. doi: 10.1056/NEJMoa1109400CrossrefMedlineGoogle Scholar4. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.Nature. 2011; 472:57–63. doi: 10.1038/nature09922CrossrefMedlineGoogle Scholar5. Yang S, Li X, Yang F, Zhao R, Pan X, Liang J, Tian L, Li X, Liu L, Xing Y, et al. Gut microbiota-dependent marker tmao in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target.Front Pharmacol. 2019; 10:1360. doi: 10.3389/fphar.2019.01360CrossrefMedlineGoogle Scholar6. Li X, Geng J, Zhao J, Ni Q, Zhao C, Zheng Y, Chen X, Wang L. Trimethylamine N-Oxide Exacerbates Cardiac Fibrosis via Activating the NLRP3 Inflammasome.Front Physiol. 2019; 10:866. doi: 10.3389/fphys.2019.00866CrossrefMedlineGoogle Scholar7. Fang C, Zuo K, Jiao K, Zhu X, Fu Y, Zhong J, Xu L, Yang X. PAGln, an Atrial Fibrillation-Linked Gut Microbial Metabolite, Acts as a Promoter of Atrial Myocyte Injury.Biomolecules. 2022; 12:1120. doi: 10.3390/biom12081120CrossrefMedlineGoogle Scholar8. Romano KN, Nemet I, Saha PP, Haghikia A, Li XS, Mohan ML, Lovano B, Castel L, Witkowski M, Buffa JA, et al. Gut microbiota-generated phenylacetylglutamine and heart failure.Circ Heart Fail. 2023; 16:74–87. doi: 10.1161/CIRCHEARTFAILURE.122.009972LinkGoogle Scholar9. Ottosson F, Brunkwall L, Smith E, Orho-Melander M, Nilsson PM, Fernandez C, Melander O. The gut microbiota-related metabolite phenylacetylglutamine associates with increased risk of incident coronary artery disease.J Hypertens. 2020; 38:2427–2434. doi: 10.1097/HJH.0000000000002569CrossrefMedlineGoogle Scholar10. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited.Circ Res. 2015; 116:1254–1268. doi: 10.1161/CIRCRESAHA.116.302317LinkGoogle Scholar11. Debras C, Chazelas E, Sellem L, Porcher R, Druesne-Pecollo N, Esseddik Y, de Edelenyi FS, Agaësse C, De Sa A, Lutchia R, et al. Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort.BMJ. 2022; 378:e071204.MedlineGoogle Scholar12. Almanza-Aguilera E, Urpi-Sarda M, Llorach R, Vázquez-Fresno R, Garcia-Aloy M, Carmona F, Sanchez A, Madrid-Gambin F, Estruch R, Corella D, et al. Microbial metabolites are associated with a high adherence to a Mediterranean dietary pattern using a (1)H-NMR-based untargeted metabolomics approach.J Nutr Biochem. 2017; 48:36–43. doi: 10.1016/j.jnutbio.2017.06.001CrossrefMedlineGoogle Scholar13. Reichard CA, Naelitz BD, Wang Z, Jia X, Li J, Stampfer MJ, Klein EA, Hazen SL, Sharifi N. Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort.Cancer Epidemiol Biomarkers Prev. 2022; 31:192–199. doi: 10.1158/1055-9965.EPI-21-0766CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesGut Microbiota-Generated Phenylacetylglutamine and Heart FailureKymberleigh A. Romano, et al. Circulation: Heart Failure. 2023;16 January 2023Vol 16, Issue 1 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/CIRCHEARTFAILURE.122.010222PMID: 36524473 Originally publishedDecember 16, 2022 Keywordsheart failureprognosiscardiovascular diseasephenylacetylglutamineEditorialsPDF download Advertisement SubjectsHeart Failure